Market Access News | pharmaphorum

News

A female palm containing a Rhapsido tablet

Rhapsido is first drug cleared for chronic hives disorder SD

Novartis' oral BTK inhibitor Rhapsido has had its label expanded in the US to include a second indication that causes chronic hives.

News

European biotech leaders say optimism is returning

Senior figures in European biopharma think dealmaking and M&A will increase in the region, and could be helped by US policy uncertainties.

News

Click claims FDA okay for first-in-class schizophrenia DTx

Click Therapeutics has won the first-ever FDA approval for a treatment for the negative symptoms of schizophrenia, a DTx called Motivista.

News

UK backs all health AI proposals in commission report

The UK will accept all 44 proposals made in a recent report on using AI tools in the NHS, including continuous monitoring after deployment.

News

Lilly's BTK drug Jaypirca joins first-line options in US

Lilly's noncovalent BTK inhibitor Jaypirca has been cleared by the FDA for its first frontline indication, but will it be reserved for later-line use?

News

Novo faces delay in US review of haemophilia drug

The FDA has extended its review of Novo's experimental haemophilia A drug denecimig because of ongoing remediation work at a manufacturing facility.

Rhapsido is first drug cleared for chronic hives disorder SD

European biotech leaders say optimism is returning

Click claims FDA okay for first-in-class schizophrenia DTx

UK backs all health AI proposals in commission report

Lilly's BTK drug Jaypirca joins first-line options in US

Novo faces delay in US review of haemophilia drug

Lilly partners with Hims & Hers on obesity drug sales

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks